Ketamine for Acute Migraine in the Emergency Department

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study will be a prospective, randomized, double-blind, placebo-controlled trial. Because ketamine has yet to be directly studied as treatment for acute migraine headache in the emergency department, the research team is initially interested if ketamine can reduce pain scores in headache patients and reduce the incidence of recurrence while exhibiting an adequate safety profile. By using a placebo-controlled study design, the research team can adequately investigate the effectiveness of the medication in a subgroup previously not well studied.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carilion Clinic
• Collaborator: Virginia Polytechnic Institute and State University
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• 18-65 years of age

• Chief complaint of headache

• International Classification of Headache Disorder classification of migraine or probable migraine with or without aura

• Has decision making capacity

• Consent

• Provider determination of non-emergent cause

Exclusion Criteria:

• Over the age of 50 with first time headache

• Known adverse reaction or tolerance to study medication

• Headache due to trauma

• New onset, focal, abnormal, neurologic findings

• New onset seizures

• History of metastatic cancer or neoplasm

• Active psychotic symptoms

• Altered mental status

• Provider intends to preform lumbar puncture

• Pregnancy

• Breast feeding

• Previous enrollment in study

• Fever > 100.3 F

• Physiologic instability (blood pressure < 90/50 or >170/100, heart rate <50 or >120, chronic respiratory, renal or hepatic failure)

• Suspected cardiac pain